Status
Conditions
Treatments
About
This is an observational, open, longitudinal, multicentre study conducted in France.
The study plans to enrol 119 patients with irritable bowel syndrome who will be included by about 50 general practitioners or gastroenterologists consulting in private offices. The treatment, Lactiplus® is a medical device, in the form of capsules containing L. gasseri LA806. The main objective of the study is to assess the effect of a 4-week treatment with the medical device on abdominal pain.
Full description
The study is designed as an observational post-market follow-up study, to confirm the performance of the medical device in real life conditions and document its safety profile.
The eligible population corresponds to the population that could benefit from the treatment, according to the MD's instructions for use. Non-inclusion criteria prevent from including patients with other pathologies associated with gastro-intestinal troubles, who may beneficiate from more adequate treatments.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal